Pulmonary embolism (PE) is a life-threatening clinical condition that is recognized as the third most common cause of cardiovascular death (Turetz et al., 2018). The relatively high mortality related to pulmonary embolism is partly due to delayed or misdiagnosis owing to its non-specific presenting symptoms; therefore, a timely and accurate diagnosis, which is highly dependent on imaging techniques, is crucial in reducing mortality (Moore et al., 2018). Computed tomography pulmonary angiography (CTPA) is currently the gold standard imaging modality for diagnosing PE (Moore et al., 2018). While acute PE could be readily diagnosed as a central filling defect surrounded by intravascular contrast, known as the polo mint and railway track signs on different imaging planes, some of the parenchymal changes that occur in the setting of acute PE are more or less non-specific. For example, pulmonary infarcts typically manifest as a wedge-shaped peripheral opacity (Wittram et al., 2004). Moreover, the atoll sign or reversed halo sign, characterized by a central zone of ground-glass opacity surrounded by a rim of dense consolidation, has been described in cases of acute PE as well as in several other lung pathologies (Almeida et al., 2020). Although a confident diagnosis can usually be made using the constellation of the mentioned radiologic findings on contrast-enhanced chest CT scan, making a correct diagnosis may be more challenging when dealing with non-contrast CT images. In fact, many patients with respiratory signs and symptoms initially undergo a non-enhanced radiologic study. This is particularly the case for many patients with coronavirus disease-2019 (COVID-19) pneumonia in whom a first-line non-contrast chest CT is performed according to national and international guidelines (Mahdavi et al., 2020; Simpson et al., 2020).

Recently, Jalaber et al. (2020) indicated that there is no clinical benefit in performing routine CTPA at initial screening in unselected COVID-19 patients; thus, CTPA might be best not to be performed systematically in all cases of COVID-19. Although to date most studies have used CTPA for the diagnosis of PE, only about 35% of patients with COVID-19 have undergone CTPA (Roncon et al., 2020). Nopp and colleagues reported that the COVID-19 pandemic lockdown caused a significant decrease in the number of diagnostic imaging tests (CTPA or V/Q lung scan) for suspected PE as compared to the corresponding periods in 2018 and 2019 in Austria (Nopp et al., 2020). Deeming the infeasibility of CTPA application in all COVID-19 cases during the height of the current pandemic, identifying patients with the highest index of suspicion for PE seems necessary for determining those in whom CTPA should be considered. On the other hand, it is also important to note that CTPA may result in the overdiagnosis of PE (Hutchinson et al., 2015) and might be associated with several potential harms, including the risk of in-hospital transmission of COVID-19, contamination of CT scanners, contrast-induced nephrotoxicity, unnecessary radiation and allergic reactions.

Peripheral opacities, including ground-glass opacities, consolidations and the atoll sign are among the most important radiologic findings of pneumonia caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (Simpson et al., 2020). Also, current evidence affirms the high prevalence of thromboembolic events, specifically PE, in patients with COVID-19 (Bikdeli et al., 2020; Klok et al., 2020); hence, care must be taken when interpreting peripheral opacities, especially the reversed halo sign, on chest CT images of those infected with the novel betacoronavirus. Herein, we present several imaging findings on non-contrast chest CT that can be suggestive of acute PE, and could thus prompt physicians to perform CTPA for confirmation of PE in COVID-19 patients.

Firstly, careful attention to the intraluminal density of a pulmonary vessel may reveal a slight increase in the focal attenuation of the vessel, marked by a hyperattenuating finding, compared with other parts. This is observed in the setting of acute PE on non-contrast CT scan, and can be explained by the higher concentration of hemoglobin in a retracting clot, commonly seen within the first seven days of PE (Morita et al., 2010; Torres et al., 2020).

Secondly, although the atoll sign has been classified as a typical imaging feature of COVID-19 pneumonia, it is usually detected in the later phases of disease (Simpson et al., 2020). On the contrary, in a recently published paper, Almeida et al. (2020) concluded that the reversed halo sign is more frequently observed in the initial scans of cases with pulmonary septic emboli and lung infarction. In PE, the underlying pathophysiology of this finding is the ischemic and hemorrhagic changes of the lung parenchyma -as opposed to organizing pneumonia that is the contributing mechanism of lung injury in COVID-19- which possibly explains the different temporal radiologic manifestations. However, further studies are needed to draw a definite conclusion.

In addition, several other ancillary findings on non-contrast chest CT, including dilatation of the pulmonary trunk and also markers suggestive of right heart strain may point out the possibility of PE (Castañer et al., 2006).

Conclusively, as radiologic findings of COVID-19 pneumonia may overlap with those of PE on non-contrast-enhanced chest CT, meticulous attention to the mentioned imaging markers, temporal radiologic changes, and clinical and laboratory parameters is mandatory. In complex clinical scenarios, evaluation by CTPA is the key to diagnosis, preventing further mortality and morbidity. Nevertheless, the decision to perform CTPA should be made if the benefits clearly outweigh its potential harms, since CT examination should be performed with the least possible harm to the patient. Until now, an established cut-off value for D-dimer has not been detected and also the relevance of conventional PE probalility scores (Wells criteria, Geneva score, and Pulmonary Embolism Rule-out Criteria) has not been studied in COVID-19 (Espallargas et al., 2020). As suggested by the pulmonary embolism response team (PERT) guideline (Rosovsky et al., 2020), a modified algorithm for the diagnosis and management of PE should be developed in this time period.

COVID-19, coronavirus disease-2019; CTPA, computed tomography pulmonary angiography; PE, pulmonary embolism; PERT, pulmonary embolism response team; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2.

All authors have participated in study design and writing of the manuscript, and have read and approved the final manuscript.

We would like to express our gratitude to all those who helped us during the writing of this manuscript.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare that they have no conflict of interest.